9180 Participants NeededMy employer runs this trial

Cefazolin for Surgical Site Infection

(CALIPSO Trial)

Recruiting at 29 trial locations
PD
SA
Overseen BySarah Astbury
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Monash University
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to evaluate the effectiveness of cefazolin, an antibiotic, in preventing infections after heart surgery. Researchers will compare three approaches: administering cefazolin only during surgery, continuing it for 24 hours afterward, or extending it to 48 hours. The goal is to determine which method best prevents surgical site infections and related issues while minimizing unnecessary medication use. Participants should be adults undergoing heart surgery that involves opening the chest, known as a median sternotomy. As a Phase 4 trial, this study involves an FDA-approved treatment and seeks to understand its benefits for a broader patient population.

What is the safety track record for cefazolin?

Research has shown that cefazolin is generally safe for preventing infections after surgery. In one study, patients who received cefazolin experienced fewer surgical site infections compared to those who received other treatments. Specifically, only 0.9% of patients in the cefazolin group developed infections, significantly lower than the 3.8% in another treatment group. Another study found that cefazolin, used as a preventive antibiotic in various surgeries, was well-tolerated by patients.

These studies suggest that cefazolin is well-tolerated and can effectively reduce the risk of infections after surgery. While some studies did not find a significant benefit for certain types of surgeries, the overall evidence supports its safety. Since the FDA has already approved cefazolin for other uses, its safety in humans is well-documented.12345

Why are researchers enthusiastic about this study treatment?

Researchers are excited about the use of cefazolin for surgical site infections because it offers a precise approach to antimicrobial prophylaxis. Unlike standard treatments that often involve a one-size-fits-all dosing schedule, this trial explores varying durations of cefazolin administration to optimize protection against infections. By tailoring the dosing schedule, researchers aim to maximize efficacy while potentially reducing unnecessary antibiotic exposure. This could lead to a more personalized and effective method for preventing infections after surgery.

What evidence suggests that this trial's treatments could be effective for preventing surgical site infections?

Studies have shown that cefazolin reduces infections at surgical sites in various operations. Specifically, it significantly lowered infection risk in planned spine surgeries. Research indicates that cefazolin is often recommended during surgery due to its effectiveness against common bacteria. However, some studies suggest that a single dose before surgery might not suffice, depending on the surgery type. This trial will compare different cefazolin dosing regimens: intraoperative only, intraoperative with 24-hour postoperative, and intraoperative with 48-hour postoperative administration, to evaluate its effectiveness in preventing surgical site infections. Overall, cefazolin is generally considered safe and effective for this purpose.46789

Who Is on the Research Team?

TP

Trisha Peel, MBBS GradCertRes FRACP PhD

Principal Investigator

Monash University

Are You a Good Fit for This Trial?

Inclusion Criteria

I am an adult having heart surgery through the chest bone.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intraoperative and postoperative antimicrobial prophylaxis with cefazolin or placebo for up to 48 hours

48 hours
In-hospital stay

Follow-up

Participants are monitored for surgical site infections and other health outcomes

90 days

Extended Follow-up

Participants are monitored for all-cause mortality and other long-term outcomes

180 days

What Are the Treatments Tested in This Trial?

Interventions

  • Cefazolin

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Intraoperative and 24-hours Postoperative Surgical Antimicrobial Prophylaxis ArmExperimental Treatment2 Interventions
Group II: Intraoperative and 48-hours Postoperative Surgical Antimicrobial Prophylaxis ArmActive Control1 Intervention
Group III: Intraoperative only Surgical Antimicrobial Prophylaxis ArmPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Monash University

Lead Sponsor

Trials
204
Recruited
10,570,000+

The Australian and New Zealand College of Anaesthetists (ANZCA)

Collaborator

Trials
1
Recruited
9,200+

ANZCA CTN

Collaborator

The Alfred

Collaborator

Trials
110
Recruited
10,030,000+

Citations

Incidence of Surgical Site Infection Despite Preoperative ...

These results are significant because they indicate the effectiveness of cefazolin in preventing surgical infection. In comparison ...

Cefazolin prophylaxis is associated with lower surgical site ...

Cefazolin prophylaxis is associated with significantly lower SSI risk in elective spine procedures. These findings support cefazolin as the preferred ...

Study reports reduced SSI odds after gynecologic surgery ...

A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries.

4.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/25052130/

The efficacy of cefazolin in reducing surgical site infection ...

Conclusions: A single dose of preoperative prophylactic cefazolin has no significant benefit in reducing the incidence of SSI in laparoscopic cholecystectomy.

Incidence of surgical infection in cefazolin 3 g versus 2 ...

Overall, these findings suggest that cefazolin 3 g surgical prophylaxis does not have an added benefit over 2 g dosing within obese populations ...

Cefazolin prophylaxis is associated with lower surgical site ...

In the present study, cefazolin-based perioperative antibiotic selection was associated with a 50% to 65% relative reduction in 90-day SSI risk ...

7.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/31950139/

Surgical site infection rate is higher following hip and knee ...

Purpose: While many guidelines recommend higher doses of cefazolin for patients with higher body weights, there are scant outcome data showing ...

1663. Risk-benefit assessment of cefazolin use for surgical ...

The frequency of SSI was lower in the cefazolin group compared to the C/V group (0.9% vs. 3.8%, p < .01). The cefazolin group included 7 SSI, ...

Effect of Antibiotic Prophylaxis on Surgical Site Infections ...

A single preoperative dose of intravenous cefazolin did not reduce the risk of surgical site infection within 30 days following removal of orthopedic implants.